CONTINGENCIES

6 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

CONTINGENCIES

NOTE G - CONTINGENCIES

The Company was able to close all open recalls with the FDA during the six months ended December 31, 2016. There were no new recall costs incurred for any recalls for the quarter ended December 31, 2016. Total recall cost incurred were $205,973 for all recalls from their start to the closure. Future recall costs are not expected.